Abstract
Tetherin (BST-2 or CD317) is an interferon-inducible cellular factor that prevents the detachment of enveloped viruses from infected cells. The primate lentiviruses have evolved different countermeasures to tetherin. The majority of SIVs use Nef to antagonize the tetherin proteins of their nonhuman primate hosts. However, due to the absence of sequences in human tetherin required for antagonism by Nef, HIV-1 Vpu and HIV-2 Env evolved to serve this function in humans. We recently identified compensatory changes in the Env cytoplasmic domain of a pathogenic nef-deleted SIV that confers resistance to rhesus macaque tetherin. These observations highlight the extraordinary plasticity of the primate lentiviruses in adapting to the tetherin proteins of their respective hosts, and reveal a prominent role for tetherin in shaping the evolution of the primate lentiviruses.
Keywords: Primate, monkey, SIV, HIV, Nef, Env, Vpu, interferon, CD317, HM1.24, restriction factor, innate immunity
Current HIV Research
Title:Adaptation of Human and Simian Immunodeficiency Viruses for Resistance to Tetherin/BST-2
Volume: 10 Issue: 4
Author(s): Ruth Serra-Moreno and David T. Evans
Affiliation:
Keywords: Primate, monkey, SIV, HIV, Nef, Env, Vpu, interferon, CD317, HM1.24, restriction factor, innate immunity
Abstract: Tetherin (BST-2 or CD317) is an interferon-inducible cellular factor that prevents the detachment of enveloped viruses from infected cells. The primate lentiviruses have evolved different countermeasures to tetherin. The majority of SIVs use Nef to antagonize the tetherin proteins of their nonhuman primate hosts. However, due to the absence of sequences in human tetherin required for antagonism by Nef, HIV-1 Vpu and HIV-2 Env evolved to serve this function in humans. We recently identified compensatory changes in the Env cytoplasmic domain of a pathogenic nef-deleted SIV that confers resistance to rhesus macaque tetherin. These observations highlight the extraordinary plasticity of the primate lentiviruses in adapting to the tetherin proteins of their respective hosts, and reveal a prominent role for tetherin in shaping the evolution of the primate lentiviruses.
Export Options
About this article
Cite this article as:
Serra-Moreno Ruth and T. Evans David, Adaptation of Human and Simian Immunodeficiency Viruses for Resistance to Tetherin/BST-2, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792496
DOI https://dx.doi.org/10.2174/157016212800792496 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry Mesothelioma - Epidemiology and Management
Current Respiratory Medicine Reviews In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Candidiasis and HIV-Protease Inhibitors: The Expected and the Unexpected
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Current Trends in the Use of Cationic Polymer Assemblies for siRNA and Plasmid DNA Delivery
Pharmaceutical Nanotechnology Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology
Current Drug Metabolism Some Personal Memories of Bob Chanock
Infectious Disorders - Drug Targets Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics Structure and Function of HIV-1 Integrase
Current Topics in Medicinal Chemistry The Role of Glycoprotein H in Herpesvirus Membrane Fusion
Protein & Peptide Letters Meridianins: Marine-Derived Potent Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Supercritical Fluid Particle Design of DPI Formulations (Review)
Current Pharmaceutical Design The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery